TY - JOUR
T1 - Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials: JACC Scientific Expert Panel
AU - Ibanez, Borja
AU - Aletras, Anthony H.
AU - Arai, Andrew E.
AU - Arheden, Hakan
AU - Bax, Jeroen
AU - Berry, Colin
AU - Bucciarelli-Ducci, Chiara
AU - Croisille, Pierre
AU - Dall'Armellina, Erica
AU - Dharmakumar, Rohan
AU - Eitel, Ingo
AU - Fernández-Jiménez, Rodrigo
AU - Friedrich, Matthias G.
AU - García-Dorado, David
AU - Hausenloy, Derek J.
AU - Kim, Raymond J.
AU - Kozerke, Sebastian
AU - Kramer, Christopher M.
AU - Salerno, Michael
AU - Sánchez-González, Javier
AU - Sanz, Javier
AU - Fuster, Valentin
PY - 2019/7/16
Y1 - 2019/7/16
N2 - © 2019 The Authors After a reperfused myocardial infarction (MI), dynamic tissue changes occur (edema, inflammation, microvascular obstruction, hemorrhage, cardiomyocyte necrosis, and ultimately replacement by fibrosis). The extension and magnitude of these changes contribute to long-term prognosis after MI. Cardiac magnetic resonance (CMR) is the gold-standard technique for noninvasive myocardial tissue characterization. CMR is also the preferred methodology for the identification of potential benefits associated with new cardioprotective strategies both in experimental and clinical trials. However, there is a wide heterogeneity in CMR methodologies used in experimental and clinical trials, including time of post-MI scan, acquisition protocols, and, more importantly, selection of endpoints. There is a need for standardization of these methodologies to improve the translation into a real clinical benefit. The main objective of this scientific expert panel consensus document is to provide recommendations for CMR endpoint selection in experimental and clinical trials based on pathophysiology and its association with hard outcomes.
AB - © 2019 The Authors After a reperfused myocardial infarction (MI), dynamic tissue changes occur (edema, inflammation, microvascular obstruction, hemorrhage, cardiomyocyte necrosis, and ultimately replacement by fibrosis). The extension and magnitude of these changes contribute to long-term prognosis after MI. Cardiac magnetic resonance (CMR) is the gold-standard technique for noninvasive myocardial tissue characterization. CMR is also the preferred methodology for the identification of potential benefits associated with new cardioprotective strategies both in experimental and clinical trials. However, there is a wide heterogeneity in CMR methodologies used in experimental and clinical trials, including time of post-MI scan, acquisition protocols, and, more importantly, selection of endpoints. There is a need for standardization of these methodologies to improve the translation into a real clinical benefit. The main objective of this scientific expert panel consensus document is to provide recommendations for CMR endpoint selection in experimental and clinical trials based on pathophysiology and its association with hard outcomes.
KW - STEMI
KW - area at risk
KW - clinical trial
KW - edema
KW - endpoint
KW - infarct size
KW - magnetic resonance imaging
KW - myocardial infarction
UR - http://www.mendeley.com/research/cardiac-mri-endpoints-myocardial-infarction-experimental-clinical-trials-jacc-scientific-expert-pane
U2 - 10.1016/j.jacc.2019.05.024
DO - 10.1016/j.jacc.2019.05.024
M3 - Review article
C2 - 31296297
SN - 0735-1097
VL - 74
SP - 238
EP - 256
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 2
ER -